Vivek Subbiah, MD · @VivekSubbiah“FDA Grants Priority Review to Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer | OncLive”
View post ↗See the full AZUR-1 KOL reaction on KOL Pulse →The Phase III WU-KONG28 trial demonstrated that the oral TKI sunvozertinib improved median PFS to 10.3 months versus 7.5 months for chemotherapy (HR 0.65) in first-line EGFR exon 20 insertion NSCLC, with an ORR of 58.9% vs 31.1%. Separately, a study in 602 patients found that adding circulating tumor RNA (ctRNA) to ctDNA liquid biopsies increased the detection of actionable rearrangements like ALK, ROS1, and RET by 38.7%.
“The clinical message is simple: A negative DNA-only liquid biopsy does not always mean there is no actionable fusion.”
— @GlopesMd · ctRNA in liquid biopsy · View post ↗📌 Amplified by @KolPulseAI
“Zidesamtinib is a next-generation ROS1 inhibitor designed for potent CNS activity and resistance coverage.”
— @GlopesMd · Zidesamtinib for ROS1+ NSCLC · View post ↗📌 Amplified by @KolPulseAI
“Take-home: An oral, chemotherapy-free first-line option has now demonstrated superior disease control in EGFR exon 20–insertion NSCLC.”
— @ChandrakanthMv · Sunvozertinib in EGFR ex20 NSCLC · View post ↗
“Less-frequent dosing could ease treatment burden and "time toxicity," keeping efficacy while giving patients back more days off therapy.”
— @LauraAlderMD · Tarlatamab in SCLC · View post ↗The European Commission today approved sacituzumab govitecan (Trodelvy) plus pembrolizumab (Keytruda) for first-line PD-L1-positive (CPS ≥10) metastatic triple-negative breast cancer, based on the Phase 3 ASCENT-04/KEYNOTE-D19 trial (NEJM, Jan 2026). The earlier ASCENT-03 trial supported the June 2026 monotherapy approval. A new analysis of the RxPONDER trial shows adjuvant chemotherapy benefit in premenopausal, HR-positive, HER2-negative, node-positive breast cancer is predicted by ovarian reserve, with an AMH level ≥10 associated with benefit (HR 0.46) while an AMH <10 was not (HR 1.27). Additionally, the NeoZanHER trial reported a 30% pCR rate using neoadjuvant zanidatamab to de-escalate therapy in small, node-negative HER2+ breast cancer, sparking comparisons to results from the PHERGain and PHERGain-2 trials.
“In a study of 177 women, fetal cells appeared in the blood of 85 percent of the healthy participants and only 64 percent of the women who had a very early, non-invasive breast cancer.”
— @anishmoonka · Microchimerism and breast cancer · View post ↗
“The premenopausal chemo benefit tracks ovarian reserve, not menopause. AMH ≥10, chemo helps (HR 0.46). AMH <10, it doesn’t (HR 1.27).”
— @DrBarbiOnc · RxPONDER AMH analysis · View post ↗📌 Amplified by @KolPulseAI
“Cross-trial comparisons are imperfect, but zanidatamab has not yet shown a stronger efficacy signal than HP. Its potential value lies in replacing two antibodies with a single bispecific agent and in refining biological selection.”
— @dr_yakupergun · NeoZanHER trial · View post ↗📌 Amplified by @KolPulseAI
The FDA granted priority review to dostarlimab for dMMR/MSI-H locally advanced rectal cancer (AZUR-1 trial), with a target action date of February 2027. This advances the immunotherapy-only 'watch and wait' approach that achieved sustained clinical complete responses in rectal cancer. The phase 2/3 STAR-TREC trial, with 12-month results published in The Lancet Oncology, evaluated chemoradiotherapy versus short-course radiotherapy for organ preservation in early and intermediate-stage rectal cancer. Additionally, data published in CA: A Cancer Journal for Clinicians showed Daraxonrasib significantly improves overall and progression-free survival in previously treated metastatic pancreatic cancer, though physicians note access challenges.
“Daraxonrasib significantly improves overall and progression‐free survival in patients with previously treated metastatic pancreatic cancer”
— @rachnatshroff · Daraxonrasib · View post ↗
“Both arms used a mesorectal-only CTV, no elective internal/external iliac nodal coverage at all, roughly half the size of a standard locally advanced rectal field.”
— @jryckman3 · STAR-TREC Trial · View post ↗
“Our small #Community Clinic w limited resources and staff, has spent several hours and emails already to get Daraxonrasib for one pancreatic patient.”
— @JasmineKambojMD · Drug Access · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
Panitumumab-based EGFR blockade showed prospective clinical activity in SMARCB1-deficient renal medullary carcinoma, a rare kidney cancer refractory to standard therapies. Separately, a new meta-analysis supporting Disease-Free Survival (DFS) as a surrogate for Overall Survival (OS) in RCC is being debated, with critiques highlighting that the correlation weakens significantly (R² drops to 0.34) when analysis is restricted to modern therapies.
“The moment you strip out the dead weight legacy trials and look only at the modern, effective, contemporary regimens (the trials that actually matter) the correlation falls apart and R² drops to 0.34. That is why the most important figure was hidden in the supplementary material (see below).”
— @HemeOncBuddy · DFS/OS Surrogacy Debate · View post ↗📌 Amplified by @KolPulseAI
“Kidney cancer has more treatments than ever. We still don’t know the best order. That is why LITESPARK-011 matters.”
— @DrYukselUrun · RCC Treatment Sequencing · View post ↗
“An interesting paper in @JournalCancer provides supportive, hypothesis-strengthening evidence for DFS as a trial-level surrogate, but not definitive validation—especially not for contemporary adjuvant immunotherapy or HIF-2–based combinations.”
— @DrChoueiri · DFS/OS Surrogacy Debate · View post ↗📌 Amplified by @KolPulseAI
Europe has approved teclistamab plus daratumumab for multiple myeloma patients who have received at least one prior therapy, based on the Phase 3 MajesTEC-3 trial, which showed a 3-year progression-free survival of 83% versus 30% with standard daratumumab-based triplets. Separately, new research on bispecific antibody therapy finds that early immune recovery (day 30 absolute lymphocyte count) is a key prognostic indicator for survival, while baseline lymphocyte count is not predictive.
“An off-the-shelf bispecific antibody combination moving much earlier in myeloma treatment.”
— @ilyassahinMD · MajesTEC-3 trial · View post ↗📌 Amplified by @KolPulseAI
“Venetoclax-dexamethasone 🆚 pomalidomide-dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma.”
— @Abdallah81MD · CANOVA trial · View post ↗📌 Amplified by @KolPulseAI
“I always use DOACs for any K + IMiD.”
— @RahulBanerjeeMD · VTE prophylaxis · View post ↗📌 Amplified by @KolPulseAI
“Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma”
— @HadidiSamer · Lymphocyte kinetics with bispecifics · View post ↗The phase II EPCORE NHL-2 trial of fixed-duration epcoritamab plus R-CHOP in newly diagnosed large B-cell lymphoma (LBCL) with an IPI score of 3-5 demonstrated high efficacy. Among 47 patients, results included a 98% overall response rate (ORR), 85% complete response rate (CRR), and at a median follow-up of 44.2 months, a 2-year progression-free survival of 80% and overall survival of 87%.
“Impressive efficacy data for Epcor+RCHOP in IPI 3-5 DLBCL n=47 ORR 98% CRR 85% At median follow-up of 44.2 months, 2-year PFS 80%, OS 87%”
— @Eddie_Cliff · Epcoritamab in 1L DLBCL · View post ↗
“#Hematology Real-world treatment patterns of patients with large B-cell lymphoma over time and into a post–CAR T approval era #lymsm #CARTcell #RWE #RWD”
— @DrRaulCordoba · RWE in LBCL · View post ↗
“2y-PFS of 80% in a ph2 will probably be a little bit less in the ph3. Will it be practice changing? Im still trying to digest all data.”
— @GuiperiniMD · EPCORE NHL-2 trial · View post ↗